bluuebunny/crossref_metadata_2025_split huggingface dataset:
Predictability of Future Attacks by Migraineurs: A Prospective Observational Study
Authors: Hu X. Henry , Golden Wendy , Bolge Susan C. , Katic Bozena , Chen Ya‐Ting , Wagner Samuel , Cady Roger 
Published: March 2010

Objective.— To determine the predictability of future migraine attacks and to describe the effect of migraine on daily life during and between migraine attacks.Background.— Migraine is associated with substantial economic and humanistic burden. There is growing evidence that early intervention with triptans results in better treatment outcomes. However, this is dependent on a patient's preparedness for an attack including having abortive medications readily accessible at headache onset.Methods.— Physician‐diagnosed adult migraine sufferers, who treat with prescription or over‐the‐counter medications, completed 2 self‐reported, Internet‐based questionnaires, administered at baseline and following the resolution of the next migraine attack. The baseline questionnaire included the Migraine Disability Assessment questionnaire (MIDAS), questions about experiences on days between attacks, predictions of the date, time of day (5 time windows), and sufferer's location (4 places) at the start of their next migraine. At follow‐up, information was collected in the similar fashion about the date, time of day, and sufferer's location at the start of their most recent migraine.Results.— A total of 1519 migraine sufferers completed the baseline questionnaire and 877 (57.7%) completed the follow‐up. At baseline, 58.7% experienced moderate to severe disability from headache, based on MIDAS. Only 4.0% were able to predict the exact date of their next migraine; 21.24% predicted next migraine within 3 days. Larger proportions (46.6%) were able to accurately predict time of day or location (70.7%) of their next migraine. In the past 3 months, 92.6% reported that they were forced to change daily plans because of migraine. Because of fear of getting a migraine, 20.2% had avoided and 27.0% had changed a work commitment, and 27.3% had avoided and 28.2% had changed social plans.Conclusions.— Migraine sufferers are generally unable to predict onset of the next migraine. Lack of predictability heightens the importance of education and preparedness for a migraine attack which may also reduce fear and anxiety between attacks.(Headache 2010;50:1296‐1305)
Selective Inhibition of 5‐HT7 Receptor Reduces CGRP Release in an Experimental Model for Migraine
Authors: Wang Xiaojuan , Fang Yannan , Liang Jianbo , Yin Zhao , Miao Jiayin , Luo Ning 
Published: March 2010

Objective.— To investigate the role of 5‐HT7 receptors on the release of calcitonin gene‐related peptide (CGRP) in an animal model of migraine.Background.— Calcitonin gene‐related peptide has been identified as a key neuropeptide in the pathophysiology of migraine. It is elevated in the external jugular vein during migraine attacks in humans and after stimulation of the trigeminal ganglion in animal models of migraine. This can be treated with the 5‐HT1B/1D receptor agonist sumatriptan concomitant with headache relief. Nevertheless, triptans, the most effective agents for the treatment of acute migraine attacks, are not effective in more than 1/3 of migraineurs and less than 50% of migraineurs achieve complete pain freedom. This indicates other serotonin receptors may be involved in the pathophysiology of migraine. Increasing evidence has shown that 5‐HT7 receptors may be involved in migraine pathogenesis. However, direct evidence for the role of 5‐HT7 receptors in migraine is still lacking.Methods.— Unilateral electrical stimulation of the trigeminal ganglion (TGES) was performed in anesthetized male Sprague‐Dawley rats. Animals were pretreated with sumatriptan (300 µg/kg, i.v.), selective 5‐HT7 receptor antagonist SB269970 (5, 10 mg/kg, s.c.), potential 5‐HT7 receptor agonist AS19 (5, 10 mg/kg, s.c.) or co‐administration of SB269970 and AS19 (10 mg/kg, s.c.). Serum CGRP concentrations in the ipsilateral jugular vein were determined before and at 2 and 5 minutes after the start of TGES.Results.— Our results showed that sumatriptan almost completely inhibited the release of CGRP evoked by TGES. Pre‐administration of SB269970 (5, 10 mg/kg) caused a significant decrease in serum CGRP concentrations at 2 and 5 minutes following the onset of TGES, with a less inhibitory effect compared with sumatriptan. AS19 had no significant effect on CGRP release, while the SB269970‐induced inhibitory effect was reversed by AS19.Conclusions.— Selective inhibition of 5‐HT7 receptors partly reduced CGRP release evoked by TGES. These findings suggest that 5‐HT7 receptors may play a role in the pathophysiology of migraine.(Headache 2010;50:579‐587)
Relationship Between Childhood Physical Maltreatment and Migraine in Adolescents
Authors: Fuh Jong‐Ling , Wang Shuu‐Jiun , Juang Kai‐Dih , Lu Shiang‐Ru , Liao Yi‐Chu , Chen Shih‐Pin 
Published: March 2010

(Headache 2010;50:761‐768)Objective.— To study the relationship between childhood physical abuse and migraine in adolescents.Background.— Childhood maltreatment might lead to an increased probability of migraine among adults. Nevertheless, the relationship between migraine and childhood abuse is unknown in adolescents.Methods.— We enrolled 3955 students, ages 13‐15, from 3 middle schools. Each participant completed a valided headache questionnaire for headache diagnosis and the Adolescent Depression Inventory (ADI). A classification of physical maltreatment was given to students who reported they had been beaten by parents or elder family members.Results.— A total of 926 (23.4%) students were diagnosed with migraine or probable migraine occurring within the 3 months prior to the survey. Physical maltreatment was reported by 945 (23.9%) students, including a frequency of “rarely” in 762 (19.3%) students and “sometimes or often” in 183 (4.6%). The students reporting physical maltreatment were more likely to suffer migraine or probable migraine compared with those who reported no physical maltreatment (30.3% vs 21.3%, odds ratios = 1.6, 95%, CI: 1.4‐1.9, P < .001). A higher frequency of physical maltreatment was associated with a higher likelihood of migraine diagnosis (21.3% vs 28.3%, vs 38.3%, “never” vs “rarely” vs “sometimes or often maltreated,” respectively, P < .001). In addition, among the students diagnosed with migraine, those reporting physical maltreatment had higher mean ADI scores, a higher frequency of headaches, and a greater proportion of severe headaches.Conclusions.— The results suggest that physical maltreatment is associated with migraine in adolescents and that physical maltreatment may be related to an increase in the frequency and intensity of headaches in adolescents with migraines. A history of physical maltreatment may be helpful in the treatment of adolescents suffering from migraine.
Variant Creutzfeldt‐Jakob disease in a transfusion recipient: coincidence or cause?
Authors: Chohan Gurjit , Llewelyn Charlotte , Mackenzie Jan , Cousens Simon , Kennedy Angus , Will Robert , Hewitt Patricia 
Published: March 2010

BACKGROUND: To date there have been four instances of infection transmitted through blood transfusions derived from individuals who later developed variant Creutzfeldt‐Jakob disease (vCJD). The identification of further transmission of vCJD through this route would have important implications for risk assessment and public health.STUDY DESIGN AND METHODS: Through the UK Transfusion Medicine Epidemiology Review (TMER) the fate of blood donations from individuals who develop vCJD is traced and recipients of labile components are identified. The details of recipients are cross‐checked with the register of vCJD cases held at the National CJD Surveillance Unit (NCJDSU) to identify any linkage between donors and recipients. In the reverse study, when individuals with vCJD are found to have a history of blood transfusion the donors of the transfused blood components are traced and their details cross‐checked with the vCJD register to identify any missed or unrecognized linkage between donors and recipients.CASE REPORT: A case of vCJD has been identified with a history of blood transfusion in infancy. The donors who provided the components transfused cannot be identified, but a blood donor known to have donated blood to another individual who subsequently developed vCJD could have been a donor to the index case.RESULTS: The at‐risk donor is alive 20 years after the relevant donation and continued to donate for some years, until identified as at risk, with 27 other blood components issued for use in patients, none of whom are known to have developed vCJD.CONCLUSION: Circumstantial evidence has raised the possibility that the case in this report represents a further instance of transfusion transmission of vCJD. However, detailed investigation indicates that the pattern of events may have occurred by chance and disease in this individual may have been caused by transmission of bovine spongiform encephalopathy infection, as is the presumed cause in other primary cases of vCJD.
Iron chelation therapy associated with improvement of hematopoiesis in transfusion‐dependent patients
Authors: Oliva Esther Natalie , Ronco Francesca , Marino Antonio , Alati Caterina , Praticò Giulia , Nobile Francesco 
Published: March 2010

BACKGROUND: It is well known that iron overload may cause multiple organ failure. In chronically transfused patients, optimal iron chelation therapy is associated with reduced morbidity and mortality. Furthermore, chelation therapy has been associated with erythroid responses.STUDY DESIGN AND METHODS: Among chronically transfused adults affected by myeloproliferative neoplasms and treated with iron chelators, two case reports are described.CASE REPORT: A male adult patient with myelodysplastic syndrome (MDS) and a female adult with aplastic anemia (AA), both transfusion‐dependent, were treated with deferasirox, an oral iron chelator.RESULTS: A significant reduction in transfusion requirement was observed and was dependent on chelation therapy. The patient affected by AA also experienced a significant increase in hemoglobin levels. Minimal doses of deferasirox maintained the erythroid responses. Many mechanisms of action of the drug on erythropoiesis have been postulated. The early erythroid response seems to be independent of the removal of iron from deposits, per se, since the reduction of ferritin levels (a surrogate marker of iron deposits) below threshold levels occurs as a later event.CONCLUSION: Although there are few reports on erythroid responses in patients undergoing iron chelation therapy, they may give new insights in the pathogenesis of MDS and other myeloproliferative neoplasms. AA may benefit in terms of erythroid response. The findings in these cases underline the clinical importance of treating patients with iron overload. A survival benefit of chelation in patients with myeloproliferative neoplasms is still to be confirmed.
Diminished Cardiac Fibrosis in Heart Failure is Associated with Altered Ventricular Arrhythmia Phenotype
Authors: MASSARE JORGE , BERRY JEFF M. , LUO XIANG , ROB FARHANA , JOHNSTONE JANET L. , SHELTON JOHN M. , BASSEL‐DUBY RHONDA , HILL JOSEPH A. , NASEEM R. HARIS 
Published: March 2010

Diminished Ventricular Fibrosis and Tachyarrhythmias. Objectives: We sought to define the role of interstitial fibrosis in the proarrhythmic phenotype of failing ventricular myocardium. Background: Multiple cellular events that occur during pathological remodeling of the failing ventricle are implicated in the genesis of ventricular tachycardia (VT), including interstitial fibrosis. Recent studies suggest that ventricular fibrosis is reversible, and current anti‐remodeling therapies attenuate ventricular fibrosis. However, the role of interstitial fibrosis in the proarrhythmic phenotype of failing ventricular myocardium is currently not well defined. Methods: Class II histone deacetylases (HDACs) have been implicated in promoting collagen biosynthesis. As these enzymes are inhibited by protein kinase D1 (PKD1), we studied mice with cardiomyocyte‐specific transgenic over‐expression of a constitutively active mutant of PKD1 (caPKD). caPKD mice were compared with animals in which cardiomyopathy was induced by severe thoracic aortic banding (sTAB). Hearts were analyzed by echocardiographic and electrocardiographic means. Interstitial fibrosis was assessed by histology and quantified biochemically. Ventricular arrhythmias were induced by closed‐chest, intracardiac pacing. Results: Similar degrees of hypertrophic growth, systolic dysfunction and mortality were observed in the two models. In sTAB mice, robust ventricular fibrosis was readily detected, but myocardial collagen content was significantly reduced in caPKD mice. As expected, VT was readily inducible by programmed stimulation in sTAB mice and VT was less inducible in caPKD mice. Surprisingly, episodes of VT manifested longer cycle lengths and longer duration in caPKD mice. Conclusion: Attenuated ventricular fibrosis is associated with reduced VT inducibility, increased VT duration, and significantly longer arrhythmia cycle length. (J Cardiovasc Electrophysiol, Vol. 21, pp. 1031‐1037, September 2010)
Beta‐Blocker Efficacy in High‐Risk Patients with the Congenital Long‐QT Syndrome Types 1 and 2: Implications for Patient Management
Authors: GOLDENBERG ILAN , BRADLEY JAMES , MOSS ARTHUR , MCNITT SCOTT , POLONSKY SLAVA , ROBINSON JENNIFER L. , ANDREWS MARK , ZAREBA WOJCIECH ,   on behalf of the International LQTS Registry Investigators
Published: March 2010

β‐Blockers for LQTS Types 1 and 2. Background: Beta‐blockers are the mainstay therapy in patients with the congenital long‐QT syndrome (LQTS) types 1 and 2. However, limited data exist regarding the efficacy and limitations of this form of medical management within high‐risk subsets of these populations. Methods and Results: Multivariate analysis was carried out to identify age‐related gender‐ and genotype‐specific risk factors for cardiac events (comprising syncope, aborted cardiac arrest [ACA] or sudden cardiac death [SCD]) from birth through age 40 years among 971 LQT1 (n = 549) and LQT2 (n = 422) patients from the International LQTS Registry. Risk factors for cardiac events included the LQT1 genotype (HR = 1.49, P = 0.003) and male gender (HR = 1.31, P = 0.04) in the 0–14 years age group; and the LQT2 genotype (HR = 1.67, P < 0.001) and female gender (HR = 2.58, P < 0.001) in the 15–40 years age group. Gender–genotype subset analysis showed enhanced risk among LQT1 males (HR = 1.93, P < 0.001) and LQT2 females (HR = 3.28, P < 0.001) in the 2 respective age groups. Beta‐blocker therapy was associated with a significant risk‐reduction in high‐risk patients, including a 67% reduction (P = 0.02) in LQT1 males and a 71% reduction (P < 0.001) in LQT2 females. Life‐threatening events (ACA/SCD) rarely occurred as a presenting symptom among beta‐blocker‐treated patients. However, high‐risk patients who experienced syncope during beta‐blocker therapy had a relatively high rate of subsequent ACA/SCD (>1 event per 100 patient‐years). Conclusions: The present findings suggest that beta‐blocker therapy should be routinely administered to all high‐risk LQT1 and LQT2 patients without contraindications as a first line measure, whereas primary defibrillator therapy should be recommended for those who experience syncope during medical therapy. (J Cardiovasc Electrophysiol, Vol. 21, pp. 893‐901, August 2010)
Preferred QT Correction Formula for the Assessment of Drug‐Induced QT Interval Prolongation
Authors: CHILADAKIS JOHN , KALOGEROPOULOS ANDREAS , ARVANITIS PANAGIOTIS , KOUTSOGIANNIS NIKOLAOS , ZAGLI FANI , ALEXOPOULOS DIMITRIOS 
Published: March 2010

Drug‐Induced QTc Interval Assessment. Introduction: There is debate on the optimal QT correction method to determine the degree of the drug‐induced QT interval prolongation in relation to heart rate (ΔQTc). Methods: Forty‐one patients (71 ± 10 years) without significant heart disease who had baseline normal QT interval with narrow QRS complexes and had been implanted with dual‐chamber pacemakers were subsequently started on antiarrhythmic drug therapy. The QTc formulas of Bazett, Fridericia, Framingham, Hodges, and Nomogram were applied to assess the effect of heart rate (baseline, atrial pacing at 60 beats/min, 80 beats/min, and 100 beats/min) on the derived ΔQTc (QTc before and during antiarrhythmic therapy). Results: Drug treatment reduced the heart rate (P < 0.001) and increased the QT interval (P < 0.001). The heart rate increase shortened the QT interval (P < 0.001) and prolonged the QTc interval (P < 0.001) by the use of all correction formulas before and during antiarrhythmic therapy. All formulas gave at 60 beats/min similar ΔQTc of 43 ± 28 ms. At heart rates slower than 60 beats/min, the Bazett and Framingham methods provided the most underestimated ΔQTc values (14 ± 32 ms and 18 ± 34 ms, respectively). At heart rates faster than 60 beats/min, the Bazett and Fridericia methods yielded the most overestimated ΔQTc values, whereas the other 3 formulas gave similar ΔQTc increases of 32 ± 28 ms. Conclusions: Bazett's formula should be avoided to assess ΔQTc at heart rates distant from 60 beats/min. The Hodges formula followed by the Nomogram method seem most appropriate in assessing ΔQTc. (J Cardiovasc Electrophysiol, Vol. 21, pp. 905‐913, August 2010)
Esophageal Endoscopy Results After Pulmonary Vein Isolation Using the Single Big Cryoballoon Technique
Authors: FÜRNKRANZ ALEXANDER , CHUN K.R. JULIAN , METZNER ANDREAS , NUYENS DIETER , SCHMIDT BORIS , BURCHARD ANDRE , TILZ ROLAND , OUYANG FEIFAN , KUCK KARL HEINZ 
Published: March 2010

Esophageal Effects of Single Big Cryoballoon PVI. Introduction: Reversible esophageal thermal lesions after cryoballoon pulmonary vein isolation (CB‐PVI) have been reported when using variable balloon sizes. The aim of this study was to investigate (1) the incidence of esophageal thermal lesions, and (2) esophageal temperature changes associated with CB‐PVI using the single big cryoballoon technique.
Methods and Results:
Thirty‐eight patients with atrial fibrillation underwent successful CB‐PVI using only the 28 mm cryoballoon. Luminal esophageal temperature (LET) was continuously monitored by 3 thermocouples. Fluoroscopic distance from cryoballoon to esophagus probe was retrospectively evaluated in RAO 30° and LAO 40° projections. All patients underwent postprocedural esophageal endoscopy. Average minimal LET was lower during freezing at inferior PVs, when compared to superior PVs: 35.4 ± 0.9 (range: 32.6 to 37.4; RSPV); 31.5 ± 7.5 (2.5 to 37.6; RIPV); 32.9 ± 5.2 (8.5 to 36.5; LSPV); and 30.3 ± 8.4°C (−6 to 36.7°C; LIPV); P = 0.001. We found steep temperature gradients over distance (1) from the cryoballoon center (LETs < 10°C confined to a distance of < 15 mm in both RAO 30° and LAO 40° projections), and (2) along the esophagus long axis, underscoring the need for multiple measurement sites. None of the patients showed esophageal thermal lesions at endoscopy after 3 ± 1 (range 1–7) days. No AEF occurred during a follow‐up of 125 ± 78 days.
Conclusion:
In a cohort of AF patients treated by the single big cryoballoon technique, CB‐PVI was not associated with thermal esophageal lesions. (J Cardiovasc Electrophysiol, Vol. 21, pp. 869‐874, August 2010)
Recanalization of Complex Coronary Chronic Total Occlusions Using High‐Frequency Vibrational Energy CROSSER Catheter as First‐Line Therapy: A Single Center Experience
Authors: GALASSI ALFREDO R , TOMASELLO SALVATORE D. , COSTANZO LUCA , CAMPISANO MARIA B. , MARZÀ FRANCESCO , TAMBURINO CORRADO 
Published: March 2010

Background: Several studies have illustrated the safety and the procedural outcome of high‐frequency vibrational energy in guidewire refractory chronic total occlusions (CTOs).
Aim: To evaluate the advantage of high‐frequency vibrational energy device (CROSSER Catheter) use in coronary complex CTO revascularization as primary strategy.
Methods: CROSSER was used as a primary approach if four or more unfavorable angiographic features were observed in the CTO lesions.
Results: From May 2007 to February 2009, a CTO percutaneous intervention attempt was performed in 178 lesions of 171 patients (60.1 ± 8.9 age with 49.4 ± 7.2% in ejection fraction). Among these, the CROSSER was used in 46 complex CTO lesions of 45 patients (25.8% of cases) and in the remaining cases, typical CTO percutaneous coronary intervention techniques were employed. Clinical success was 84.8% in CROSSER group. Moreover, in the CROSSER group, no periprocedural myocardial infarction, perforation, or 30 days MACE was observed. In addition, the use of CROSSER was associated with lower time of procedure, time of fluoroscopy, and contrast load administration as compared with conventional techniques [88 ± 27 minutes vs 109 ± 38 minutes (P = 0.045), 39 ± 12 minutes vs 50 ± 27 minutes (P = 0.032), and 334 ± 122cc vs 408 ± 198cc (P = 0.05), respectively].
Conclusion: In the present study, the CROSSER System was safe and obtained a high rate of success in complex CTO similar to conventional dedicated guidewire techniques for noncomplex CTO; however, the CROSSER Catheter obtained CTO recanalization with lower contrast load administration, less time of procedure, and lower fluoroscopy exposure. (J Interven Cardiol 2010;23:130‐138)
The Paclitaxel‐Eluting Coroflex™ Stent Study II (PECOPS II) Acute and 6‐Month Clinical and Angiographic Follow‐Up, 1‐Year Clinical Follow‐Up
Authors: WIEMER MARCUS , DEGENHARDT RALF , VALLBRACHT CHRISTIAN , HORSTKOTTE DIETER , SCHNEIDER HENRIK , NIENABER CHRISTOPH , BOCKSCH WOLFGANG , BOXBERGER MICHAEL , UNVERDORBEN MARTIN ,   for the PECOPS II Investigators
Published: March 2010

Background and Objectives: Paclitaxel‐coated stents have proven their efficacy for reducing restenosis in de novo coronary artery lesions and in‐stent restenoses with superiority compared to bare metal stents. This study was performed to evaluate the procedural and 1 year results of the Paclitaxel‐eluting Coroflex™ Please stent in coronary artery lesions.
Methods: One‐hundred and twenty‐nine patients (66.2 ± 8.2 years, 31.0% diabetics, 20.2% unstable angina, 41.8% multivessel disease) were enrolled per protocol for elective single stent deployment into native de novo or post‐PTCA restenotic coronary lesions.The mean reference diameter was 2.84 ± 0.43 mm, the lesion length 12.51 ± 4.6 mm, and the minimal lumen diameter 0.75 ± 0.29 mm. Follow‐up was performed clinically in 129/129 (100%) after 6 and 12 months and angiographically in 120/129 (93%) patients after 6 months.
Results: The success rates of the procedure and deployment were 100% and 95.3%, respectively. The in‐stent late loss and the late‐loss index were 0.27 ± 0.59 mm and 0.17 ± 0.40 resulting in binary in‐stent restenoses in 16/120 (13.3%) subjects and in‐segment restenoses in 20/120 (16.7%) subjects. Major adverse cardiac events occurred in 23/129 (17.8%) during the first 6 months of follow‐up with 3/129 (2.3%) myocardial infarctions, 1/129 (0.8%) secondary to stent thrombosis. From 6 to 12 months, 2/129 (1.6%) nonlesion related PCI were performed.
Conclusion: The data of the Paclitaxel‐eluting Coroflex™ Please stent evaluated in PECOPS II are within the range of the other currently available Paclitaxel‐eluting stent. (J Interven Cardiol 2010;23:160‐166)